Is HPS2-THRIVE the death knell for niacin?

Authors

Peter P. Toth, CGH Medical Center, Sterling, IL, USA; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Avinash M. Murthy, Department of Medicine, Bridgeport Hospital, Yale New Haven Health System, Yale University School of Medicine, Bridgeport, CT, USA.
Mandeep S. Sidhu, Department of Medicine, Albany Stratton VA Medical Center and Albany Medical Center, Albany Medical College, Albany, NY, USA.
William E. Boden, Department of Medicine, Albany Stratton VA Medical Center and Albany Medical Center, Albany Medical College, Albany, NY, USA. Electronic address: William.boden@va.gov.

Document Type

Article

Publication Title

Journal of clinical lipidology

Abstract

Niacin is a lipid-modifying therapy with proven efficacy for reducing cardiovascular events as monotherapy and when used in combination with other lipid-modifying medications impacts rates of atherosclerotic disease progression. Large outcome trials using niacin against a background of statin therapy with optimal control of atherogenic lipoprotein burden in serum were unable to demonstrate incremental benefit of niacin beyond statin therapy. We address 2 key questions: (1) Can the results from randomized clinical trials performed in stable ischemic heart disease populations (AIM-HIGH and HPS2-THRIVE) be applied to patients who sustain an acute coronary syndrome or myocardial infarction? (2) Are patients with very low baseline levels of high-density lipoprotein cholesterol (<30 mg/dL) at particularly high risk for subsequent cardiac events?

First Page

343

Last Page

50

DOI

10.1016/j.jacl.2015.01.008

Publication Date

1-1-2015

Recommended Citation

Toth, Peter P.; Murthy, Avinash M.; Sidhu, Mandeep S.; and Boden, William E., "Is HPS2-THRIVE the death knell for niacin?" (2015). Randomized Controlled Trial. 29.
https://scholar.bridgeporthospital.org/randomized_trial/29

Identifier

26073392 (pubmed); 10.1016/j.jacl.2015.01.008 (doi); S1933-2874(15)00044-6 (pii)